¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧ1998ÄêÃâÒßѧ£¨²©Ê¿£©
¼¶±ð: ²©Ê¿
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-20   

µÚËľüÒ½´óѧ1998ÄêÃâÒßѧ£¨²©Ê¿£©

µÚËľüÒ½´óѧ1998ÄêÃâÒßѧ£¨²©Ê¿£© G  ZDyw9  
|zKFF?7#wE  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© dNUi|IYm$  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© %}J[EV  
1.Co-stimulators (or co-stimulating molecules) :54ik,l  
2.NK-kB wzwEYZN(q  
3.Immunoglobulin superfamily '-N `u$3Y  
4.antigen-presenting cell (APC) *:{s|18Pj  
5.death domain nQy.?*X  
6.CCR and CXCR  _zvCc%  
7.Lectin (or mitogen) %JF^@\E!|  
8.Clusters of differentiation, CD) ikX"f?Q;S2  
9.B7 family %IL] Wz<  
10.Cytotoxic T lymphocyte, CTL) B52n'.  
11.IL-15 and IL-15 receptor (IL-15R) )S@e&a|  
12.MHC restriction JZI)jIh  
13.Affinity-chromatography `?E|frz[  
14.Cyctosprin A, CsA nWb*u  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC)  bi/ AQ^  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© iZY4+ X  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 QTr) r;Tro  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ C2}n &{T  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢á¹¹¼°Æäʶ±?¿¹Ô­µÄÌØµã¡£ yX 9 .yq  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© 3 PkVMX  
ÃâÒßѧרҵ£º {=K);z  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ )qSjI_qt5  
Ïû»¯ÄÚ¿Æ£º 9K!kU6Gh  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ s.|OdC>U =  
ѪҺ²¡Ñ§×¨Òµ£º |7%has3"  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»